Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.
In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.
Building on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。